Skip to main content
. Author manuscript; available in PMC: 2014 Sep 8.
Published in final edited form as: Semin Hematol. 2012 Oct;49(4):304–311. doi: 10.1053/j.seminhematol.2012.07.004

Table 1. MDS characteristics and response to IST3, 26.

Variable Impact
Favorable No effect Unfavorable
Disease status RA, RAEB, IPSS low/int-1 RARS, Secondary MDS Advanced MDS
HLA type DR15
Age <60 years
Sex female
Duration of transfusion dependence short
Karyotype trisomy 8 other karyotype
IST regimen ATG+CSA
Other PNH Hypoplastic marrow